Company Product Description Indication Status
Oncoimmune Inc., of Rockville, Md. ONC-392 Next-generation anti-CTLA4 antibody Advanced solid tumors FDA cleared IND for phase Ia/IIb study to test drug as single agent in advanced solid tumors and in combination with anti-PD-(L)1 standard of care in non-small-cell lung cancer; study expected to start in early 2020
Urovant Sciences Ltd., of Irvine, Calif., and Basel, Switzerland Vibegron Once-daily beta-3 adrenergic agonist Overactive bladder Submitted NDA to FDA seeking approval to treat patients with symptoms of urge urinary incontinence, urgency and urinary frequency


For more information about individual companies and/or products, see Cortellis.

No Comments